Park Ha Biological Technology (BYAH) Cash & Equivalents (2023 - 2026)

Park Ha Biological Technology (BYAH) has reported Cash & Equivalents for 4 consecutive years, with $627851.0 the latest figure, recorded in Q2 2026.

• Quarterly Cash & Equivalents fell 53.54% year-over-year to $627851.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $627851.0 (down 53.54% YoY) and the FY2025 annual result came in at $3.8 million, up 591.82% from the prior year.
• Cash & Equivalents eased to $627851.0 in Q2 2026 per BYAH's latest filing, from $3.8 million in the prior quarter.
• Over the last five years, Cash & Equivalents for BYAH reached as high as $3.8 million in Q4 2025 and fell as low as $547498.0 in Q4 2024.
• A 4-year average of $1.5 million and a median of $1.0 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2025 — Cash & Equivalents soared 591.82% — and 2026, when it slumped 53.54%.
• Year by year, Cash & Equivalents stood at $1.0 million in 2023, then slumped by 47.03% to $547498.0 in 2024, then surged by 591.82% to $3.8 million in 2025, then tumbled by 83.42% to $627851.0 in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $627851.0, $3.8 million, and $1.4 million for Q2 2026, Q4 2025, and Q2 2025 respectively.